GRAIL told the market on February 19, 2026 that its NHS-Galleri trial had not hit its main target. By the close of trading the next day, the stock was down more than half. Shareholders who bought during the period before that announcement now accuse the company of misleading them about how the trial was built.
The law firm Bleichmar Fonti & Auld LLP said on June 30 that a securities fraud class action has been filed against GRAIL, Inc. (Nasdaq: GRAL) and certain senior executives. The complaint, captioned Robbins v. GRAIL, Inc., et al., No. 26-cv-05428, is pending in the U.S. District Court for the Northern District of California. It asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The deadline for investors to ask to be named lead plaintiff is August 4, 2026.
What the complaint says
GRAIL is a commercial-stage healthcare company focused on early cancer detection. Its Galleri test analyzes a blood sample to screen for multiple cancers. The NHS-Galleri trial was part of the company’s effort to see the test adopted as a national screening program in the United Kingdom, and it aimed to show fewer late-stage (III-IV) cancers among people who got the test than among those who did not.
The plaintiffs point to GRAIL’s public statements during the relevant period. Among them: the trial was “designed with three consecutive years of screening in order to achieve the primary endpoint.” The complaint says that was untrue, because three years could not demonstrate the endpoint.
The numbers
GRAIL’s February 19 announcement included some results the company described as favorable. It also said the “primary endpoint of statistically significant Stage III-IV reduction was not observed,” and suggested a longer follow-up was probably needed.
The stock fell from $101.53 on February 19 to $50.21 on February 20. A loss of $51.32 a share, or 50.55%.
The claims are allegations only. No court has ruled on whether GRAIL or its executives broke any law.





